Delving into the Latest Updates on A. Carlsson Research AB with Synapse

Overview

An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309

Start Date08 Jan 2014

Sponsor / Collaborator

A. Carlsson Research AB

EUCTR2011-003133-34-SE / Not yet recruitingPhase 2

The Effects of the Dopamine Stabilizer (-)-OSU6162 on Craving and Impulsivity in Alcohol Dependent Patients

Start Date29 Feb 2012

Sponsor / Collaborator

A. Carlsson Research AB

EUCTR2011-004357-82-SE / Not yet recruitingPhase 2

A randomized controlled trial of OSU6162 in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Start Date21 Feb 2012

Sponsor / Collaborator

A. Carlsson Research AB

100 Clinical Results associated with A. Carlsson Research AB

Login to view more data

0 Patents (Medical) associated with A. Carlsson Research AB

Login to view more data

3

Literatures (Medical) associated with A. Carlsson Research AB

01 Jun 2018·Acta Neuropsychiatrica

A randomised controlled trial of the monoaminergic stabiliser (−)-OSU6162 in treatment of myalgic encephalomyelitis/chronic fatigue syndrome

Article

Author: Zachrisson, Olof ; Carlsson, Arvid ; Nilsson, Marie Karin Lena ; Matousek, Michael ; Gottfries, Carl-Gerhard ; Schuit, Robert Christiaan ; Kloberg, Angelica ; Carlsson, Maria Lizzie ; Forsmark, Sara ; Peilot, Birgitta

ObjectiveThe monoaminergic stabiliser (−)-OSU6162 has in previous studies shown promising effects on mental fatigue after stroke and traumatic brain injury. This study investigated the safety and effectiveness of (−)-OSU6162 in patients with myalgic encephalomyelitis/chronic fatigue syndrome.MethodsA total of 62 patients were randomly assigned to placebo or (−)-OSU6162. Primary outcomes were assessment on the mental fatigue scale (MFS) and the clinical global impression of change (CGI-C) scale. Secondary outcomes were results on the FibroFatigue scale (FF), the Beck Depression Inventory (BDI), the pain visual analogue scale and neuropsychological tests. Assessments were performed at baseline, after 1 and 2 weeks of treatment and at follow-up after 6 weeks.ResultsMFS and CGI-C showed significant improvements for both treatment groups after treatment but not at follow-up; a similar pattern was seen for FF and BDI. However, significant differences between groups could not be demonstrated. On the other hand, correlation analyses showed a significant correlation between (−)-OSU6162 concentration and change in MFS, FF, and BDI score within the concentration interval 0.1–0.7 µM. Exploratory subgroup analyses showed a larger treatment effect with (−)-OSU6162 in improving MFS and FF symptoms in patients on antidepressant therapy compared to those without antidepressant treatment.Conclusion(−)-OSU6162 was found to be safe and well tolerated. When analysing the entire material (−)-OSU6162 was not found to differ significantly from placebo in alleviating fatigue in ME patients but was superior to placebo in counteracting fatigue in a subgroup of ME patients who received concomitant pharmacological treatment for depression.

01 Oct 2014·Acta Neuropsychiatrica

Tolerability and efficacy of the monoaminergic stabilizer (−)-OSU6162 (PNU-96391A) in Huntington’s disease: a double-blind cross-over study

Article

Author: Carlsson, Arvid ; Kloberg, Angelica ; Carlsson, Maria Lizzie ; Nilsson, Marie Karin Lena ; Wahlström, Jan ; Constantinescu, Radu ; Haghighi, Sara

ObjectiveTo evaluate the safety (primary objective) and efficacy (secondary objective) of (−)-OSU6162 in Huntington’s disease (HD).MethodsIn a double-blind, cross-over trial, patients with HD were randomly assigned to start treatment on either (−)-OSU6162 or placebo. After 4 weeks, those patients who initially received active drug were switched to placebo for another 4 weeks, and vice versa. During the first week the (−)-OSU6162 dose was 15 mg twice daily, during the second week 30 mg twice daily, and during the last 2 weeks 45 mg twice daily. Motor, cognitive, mental and social functions were rated by the clinical investigator or by self-assessment, using established rating scales.ResultsFifteen patients fulfilling inclusion and exclusion criteria completed the study. (−)-OSU6162 was well tolerated by all patients and no adverse effects were observed. (−)-OSU6162 treatment significantly improved the Short Form 36 Vitality score, mainly due to an improvement of the individual item ‘worn-out’ (VT3). In addition, an improvement of depressive symptoms was found using Beck Depression Inventory. In contrast to a general trend of improvement in several non-motor variables only small and non-significant differences between (−)-OSU6162 and placebo were found regarding motor functions.Conclusions(−)-OSU6162 offers promise for the treatment of HD, as a drug with good tolerability, capable of improving the patients’ experienced non-motor functions such as energy and mood and thus alleviating symptoms of great importance for their quality of life.

The neuroregulatory properties of levodopa: evidence and potential role in the treatment of Parkinson's disease

Author: Tedroff, Joakim

A review discusses the potential implications for changes in levodopa pharmacodynamics with progression of Parkinson's disease.

100 Deals associated with A. Carlsson Research AB

Login to view more data

100 Translational Medicine associated with A. Carlsson Research AB

Login to view more data